Clinical Trials Browser

Lymphoma × daratumumab × Clear all

NCT07513129 2026-04-13

A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Phase 2/3 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04915248 2025-12-24

FIL_DALYA

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

NCT06398457 2025-09-26

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Phase EARLY_PHASE1 Recruiting

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02927925 2021-01-14

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Phase 2 Completed

32 enrolled 17 charts

Lymphoma